hemCheck approved for trading on Nasdaq First North – Regulatory

This Press Release should not be released or distributed, directly or indirectly, within USA, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa, New Zealand or any other jurisdictions where distribution would be subject to legal restrictions.

Nasdaq First North has approved hemCheck Sweden AB’s (publ) (‘hemCheck’ or the ‘Company’) application for listing of the Company’s shares, and subscription option rights of series TO 1, for admission for trading on Nasdaq First North. The first trading day will be 15 March 2017. The ticker symbol for the Company’s shares on First North is HEMC, the ticker symbol for the subscription option rights is HEMC TO 1.

hemCheck develops and commercializes a unique product concept (Helge(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Nasdaq Stockholm AB has approved hemCheck’s application for the Company’s shares and subscription option rights (series TO 1) to begin trading on Nasdaq First North. The first day of trading will be March 15, 2017.

hemCheck CEO Annelie Brolinson:
“We’re delighted interest in our share issue has been so great. We look forward to begin trading on 15 March. The whole team at hemCheck will continue to keep working hard to meet all our shareholders’ expectations. As previously announced we will now finalize our product concept, consisting of Helge(TM) and READY(TM), for CE marking. We can then go full speed ahead with the market launch of our concept, starting in Sweden.”

Background
In February hemCheck announced that the company had received over 1900 new shareholders through a new issue of units. Each unit consisted of one share and one subscription option rights of series TO 1. With subscription option rights issued free of charge the subscription price per unit amounted to SEK 6 per share. The issue volume of 28.2 million initially signed to approximately 59 MSEK, a subscription rate equivalent to approx. 209%. As the rights issue was oversubscribed, the Board decided to make full use of an over-allotted issue. The company thus initially raised approx. 30 MSEK prior to listing, and if all share issue costs and / or all outstanding subscription option rights will be used before Q1 2018, the Company will receive an additional 30 MSEK before issue costs.

The ticker symbol for the Company’s shares on First North is HEMC, the ticker symbol for subscription option rights is HEMC TO 1.

Conditions for subscription option rights
Possession of a series TO 1 subscription option rights entitles the owner to subscribe for one of the new shares at a price of SEK 6 for a period from 29 January 2018, up to and including 9 February 2018.

Full details on how warrants will be used for subscription of shares in hemCheck will be made available on the Company’s website,www.hemcheck.com, and Aktieinvest’s website www.aktieinvest.se from 29 January 2018. Full terms and conditions for the warrants of series TO 1 will be detailed in the section Full terms and conditions for the warrants of series TO 1 in the prospectus being prepared for the new share issue, which is available on the Company website.

Advisors
Corpura AB is the financial advisor for the new share issue, and Fredersen Advokatbyrå AB is acting legal advisor. hemCheck’s Certified Adviser on Nasdaq First North will be Corpura AB. Aktieinvest FK AB is acting as receiving agent in connection with the rights issue.

About hemCheck
hemCheck Sweden AB (publ) develops and commercializes a unique product concept (HELGE(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples being unfit for analysis-which can lead to poorer healthcare, increased risk for patients and higher costs for clinics and society. By detecting hemolysis in blood tests directly, HELGE(TM) can contribute to improved care for patients throughout the world. hemCheck is headquartered in Karlstad, Sweden. hemCheck prepared a prospectus for the issue of new units before its resumption of trading on Nasdaq First North.

Contact
hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
E-post: annelie.brolinson@hemcheck.com
Universitetsgatan 2
651 88 Karlstad
www.hemcheck.com

Important information
The information in this press release may not be published, reproduced or distributed in or into the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or other jurisdiction where such action is not permitted, or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.

No interim units or units have been registered and will not be registered under the United States Securities Act of 1933 (the ‘Securities Act’) and may not be offered, subscribed to, sold or transferred, directly or indirectly, within the United States, except with the written approval from hemCheck and pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United states.

This is information which hemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person’s auspices, for publication on 13 March 2017, 1725.